[{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vallon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"immediate release tablet","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended-release tablet","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablets","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"CNS","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Aytu BioPharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Pediatrix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Pediatrix Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Pediatrix Therapeutics"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cediprof","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Dextroamphetamine Saccharate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Cediprof","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Cediprof"},{"orgOrder":0,"company":"Medomie","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Medomie","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Medomie \/ Aytu BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Medomie \/ Aytu BioPharma"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Aardvark Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GRI Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"Immediate-Release Tablet","sponsorNew":"GRI Bio \/ Aardvark Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"GRI Bio \/ Aardvark Therapeutics"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Perigon Pharmacy 360","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Perigon Pharmacy 360","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Perigon Pharmacy 360"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dextroamphetamine Saccharate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Lupin Pharma Canada","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Amphetamine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aytu BioPharma \/ Lupin Pharma Canada","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioPharma \/ Lupin Pharma Canada"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dextroamphetamine Saccharate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Amphetamine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Dextroamphetamine Sulfate is a non-catecholamine sympathomimetic amines with CNS stimulant activity. It is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extr...

                          Brand Name : Amphetamine-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 24, 2023

                          Lead Product(s) : Amphetamine,Dextroamphetamine Saccharate,Amphetamine Aspartate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Granules India

                          02

                          Details : FDA approved generic of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, for Attention Deficit Hyperactivity Disorder and Narcolepsy.

                          Brand Name : Adderall-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 30, 2021

                          Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Granules India

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Adderall XR-Generic is a combination product of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate & amphetamine sulfate. It is indicated for ADHD.

                          Brand Name : Adderall XR-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 21, 2024

                          Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The agreement aims for the distribution and supply for Aytu's Adzenys XR-ODT and Cotempla XR-ODT product lines for the treatment of ADHD in Canada.

                          Brand Name : Adzenys XR-ODT

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 01, 2024

                          Lead Product(s) : Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Lupin Pharma Canada

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Tris Pharma and Perigon launched a direct-to-patient program, that allows patients and caregivers access to DYANAVEL XR (amphetamine) extended-release tablets through Perigon’s digital pharmacy and receive assistance and support to help navigate their ...

                          Brand Name : Dyanavel XR

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 30, 2023

                          Lead Product(s) : Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Perigon Pharmacy 360

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Aardvark will acquire certain assets and intellectual property of the Company that pertain to ADAIR, a proprietary abuse-deterrent formulation of immediate release dextroamphetamine, for the development of certain follow-on pipeline ...

                          Brand Name : ADAIR

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 23, 2023

                          Lead Product(s) : Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Aardvark Therapeutics

                          Deal Size : $80.0 million

                          Deal Type : Agreement

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Medomie will commercialize Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) in Israel and the Palestinian Authority.

                          Brand Name : Adzenys XR

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 31, 2023

                          Lead Product(s) : Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Aytu BioPharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Glenmark will distribute Cediprof's FDA approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), the generic version...

                          Brand Name : Adderall-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 09, 2023

                          Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Cediprof

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Xelstrym™ (dextroamphetamine) is a first and only FDA-approved, once-daily central nervous system stimulant transdermal patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

                          Brand Name : Xelstrym

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 10, 2023

                          Lead Product(s) : Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Dyanavel XR oral suspension (amphetamine) is a CNS stimulant that affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control used for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years a...

                          Brand Name : Dyanavel XR

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 01, 2022

                          Lead Product(s) : Amphetamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Pediatrix Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank